Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2364533
Max Phase: Preclinical
Molecular Formula: C22H34O4
Molecular Weight: 362.51
Molecule Type: Small molecule
Associated Items:
ID: ALA2364533
Max Phase: Preclinical
Molecular Formula: C22H34O4
Molecular Weight: 362.51
Molecule Type: Small molecule
Associated Items:
Synonyms (1): 11,17,21-trihydroxy-2R-methyl-4-pregnene-3,20-dione
Synonyms from Alternative Forms(1):
Canonical SMILES: C[C@@H]1C[C@@]2(C)C(=CC1=O)CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)CCO
Standard InChI: InChI=1S/C22H34O4/c1-13-11-20(2)14(10-17(13)24)4-5-15-16-6-7-22(26,8-9-23)21(16,3)12-18(25)19(15)20/h10,13,15-16,18-19,23,25-26H,4-9,11-12H2,1-3H3/t13-,15+,16+,18+,19-,20+,21+,22+/m1/s1
Standard InChI Key: ONTQMOVIAFKBCE-HHLDKIARSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 362.51 | Molecular Weight (Monoisotopic): 362.2457 | AlogP: 2.85 | #Rotatable Bonds: 2 |
Polar Surface Area: 77.76 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 3 |
#RO5 Violations: 0 | HBA (Lipinski): 4 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: | CX LogP: 1.89 | CX LogD: 1.89 |
Aromatic Rings: 0 | Heavy Atoms: 26 | QED Weighted: 0.71 | Np Likeness Score: 2.42 |
1. Stiefl N, Baumann K.. (2003) Mapping property distributions of molecular surfaces: algorithm and evaluation of a novel 3D quantitative structure-activity relationship technique., 46 (8): [PMID:12672239] [10.1021/jm021077w] |
2. Silverman BD, Platt DE.. (1996) Comparative molecular moment analysis (CoMMA): 3D-QSAR without molecular superposition., 39 (11): [PMID:8667357] [10.1021/jm950589q] |
3. Jain AN, Koile K, Chapman D.. (1994) Compass: predicting biological activities from molecular surface properties. Performance comparisons on a steroid benchmark., 37 (15): [PMID:8057280] [10.1021/jm00041a010] |
4. Kubinyi H, Hamprecht FA, Mietzner T.. (1998) Three-dimensional quantitative similarity-activity relationships (3D QSiAR) from SEAL similarity matrices., 41 (14): [PMID:9651159] [10.1021/jm970732a] |
5. Crippen GM.. (1997) Validation of EGSITE2, a mixed integer program for deducing objective site models for experimental binding data., 40 (20): [PMID:9379435] [10.1021/jm970211n] |
6. Pastor M, Cruciani G, McLay I, Pickett S, Clementi S.. (2000) GRid-INdependent descriptors (GRIND): a novel class of alignment-independent three-dimensional molecular descriptors., 43 (17): [PMID:10966742] [10.1021/jm000941m] |
7. Bodor N, Harget AJ, Phillips EW.. (1983) Structure-activity relationships in the antiinflammatory steroids: a pattern-recognition approach., 26 (3): [PMID:6827553] [10.1021/jm00357a003] |
8. So SS, Karplus M.. (1997) Three-dimensional quantitative structure-activity relationships from molecular similarity matrices and genetic neural networks. 1. Method and validations., 40 (26): [PMID:9435904] [10.1021/jm970487v] |
9. Good AC, So SS, Richards WG.. (1993) Structure-activity relationships from molecular similarity matrices., 36 (4): [PMID:8474098] [10.1021/jm00056a002] |
10. Robinson DD, Winn PJ, Lyne PD, Richards WG.. (1999) Self-organizing molecular field analysis: a tool for structure-activity studies., 42 (4): [PMID:10052964] [10.1021/jm9810607] |
Source(1):